Mylan Launches Generic Xeloda® Tablets

                    Mylan Launches Generic Xeloda® Tablets

PR Newswire

PITTSBURGH, Aug. 11, 2014

PITTSBURGH, Aug. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg,
the generic version of Genentech's Xeloda® Tablets. Mylan received final
approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated
New Drug Application (ANDA) for this product, which is indicated as
monotherapy, adjuvant therapy and combination therapy for certain types of
breast, colon and colorectal cancers.(1)

CEO Heather Bresch commented, "The approval of this product, one of a number
of key approvals that had been pending with FDA, adds an important product to
our broad and growing oncology franchise. We look forward to bringing a lower
cost generic version of this product to patients."

Capecitabine Tablets USP, 150 mg and 500 mg, had U.S. sales of approximately
$773.8 million for the 12 months ending June 30, 2014, according to IMS

Currently, Mylan has 296 ANDAs pending FDA approval representing $106 billion
in annual brand sales, according to IMS Health. Forty-three of these pending
ANDAs are potential first-to-file opportunities, representing $25.0 billion in
annual brand sales, for the 12 months ending Dec. 31, 2013, according to IMS

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside.

(1) Patients taking Capecitabine in combination with anticoagulation drugs,
like warfarin and phenprocoumon, should have their coagulation response
monitored frequently. Capecitabine is not indicated in patients with
dihydropyrimidine dehydrogenase deficiency, severe renal insufficiency or a
known hypersensitivity to capecitabine or any of its components.

This press release includes statements that constitute "forward-looking
statements," including with regard to sales of products. These statements are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Because such statements inherently involve
risks and uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause or contribute to such differences include, but are not limited to:
strategies by competitors or other third parties to delay or prevent product
introductions; risks inherent in legal and regulatory processes; and the other
risks detailed in the company's filings with the Securities and Exchange
Commission. The company undertakes no obligation to update these statements
for revisions or changes after the date of this release.

SOURCE Mylan Inc.

Contact: Nina Devlin (Media), 724.514.1968, Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.